Evangelia K. Papachristou

Evangelia K. Papachristou

Auto-generated profile, based on publicly available information

Evangelia K. Papachristou

Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2016 in Nature Protocols
Verified
Journal Article
Closed access
HMHisham Mohammed
Hisham Mohammed
CTChristopher Taylor
Christopher Taylor
GBGordon D Brown
Gordon D Brown
EPEvaggelia K Papachristou
Evaggelia K Papachristou
JCJason S Carroll
Jason S Carroll
CDClive DSantos
Clive DSantos

6 January 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SNSankari Nagarajan
Sankari Nagarajan
SRShalini V. Rao
Shalini V. Rao
JSJoseph Sutton
Joseph Sutton
DCDanya Cheeseman
Danya Cheeseman
SDShanade Dunn
Shanade Dunn
JCJason S. Carroll
Jason S. Carroll

13 June 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
EPEvangelia K. Papachristou
Evangelia K. Papachristou
KKKamal Kishore
Kamal Kishore
AHAndrew N. Holding
Andrew N. Holding
KHKate Harvey
Kate Harvey
TRTheodoros I. Roumeliotis
Theodoros I. Roumeliotis
JCJason S. Carroll
Jason S. Carroll
Understanding the dynamics of endogenous protein–protein interactions in complex networks is pivotal in deciphering disease mechanisms. To enable the in-depth analysis of protein interactions in chromatin-associated protein complexes, we have previously developed a method termed RIME (Rapid Immunoprecipitation Mass spectrometry of Endogenous proteins). Here, we present a quantitative multiplexed method (qPLEX-RIME), which integrates RIME with isobaric labelling and tribrid mass spectrometry for the study of protein interactome dynamics in a quantitative fashion with increased sensitivity. Using the qPLEX-RIME method, we delineate the temporal changes of the Estrogen Receptor alpha (ERα) interactome in breast cancer cells treated with 4-hydroxytamoxifen. Furthermore, we identify endogenous ERα-associated proteins in human Patient-Derived Xenograft tumours and in primary human breast cancer clinical tissue. Our results demonstrate that the combination of RIME with isobaric labelling offers a powerful tool for the in-depth and quantitative characterisation of protein interactome dynamics, which is applicable to clinical samples.

8 June 2022 in Nature
Verified
Journal Article
Open access
PDF file
SPSaroor A. Patel
Saroor A. Patel
SHShoko Hirosue
Shoko Hirosue
PRPaulo Rodrigues
Paulo Rodrigues
EVErika Vojtasova
Erika Vojtasova
EREmma K. Richardson
Emma K. Richardson
SVSakari Vanharanta
Sakari Vanharanta
Large-scale human genetic data1–3 have shown that cancer mutations display strong tissue-selectivity, but how this selectivity arises remains unclear. Here, using experimental models, functional genomics and analyses of patient samples, we demonstrate that the lineage transcription factor paired box 8 (PAX8) is required for oncogenic signalling by two common genetic alterations that cause clear cell renal cell carcinoma (ccRCC) in humans: the germline variant rs7948643 at 11q13.3 and somatic inactivation of the von Hippel-Lindau tumour suppressor (VHL)4–6. VHL loss, which is observed in about 90% of ccRCCs, can lead to hypoxia-inducible factor 2α (HIF2A) stabilization6,7. We show that HIF2A is preferentially recruited to PAX8-bound transcriptional enhancers, including a pro-tumorigenic cyclin D1 (CCND1) enhancer that is controlled by PAX8 and HIF2A. The ccRCC-protective allele C at rs7948643 inhibits PAX8 binding at this enhancer and downstream activation of CCND1 expression. Co-option of a PAX8-dependent physiological programme that supports the proliferation of normal renal epithelial cells is also required for MYC expression from the ccRCC metastasis-associated amplicons at 8q21.3-q24.3 (ref. 8). These results demonstrate that transcriptional lineage factors are essential for oncogenic signalling and that they mediate tissue-specific cancer risk associated with somatic and inherited genetic variants.

1 October 2017 in Cell Reports
Verified
Journal Article
Open access
PTPetros A. Tyrakis
Petros A. Tyrakis
MYMarie E. Yurkovich
Marie E. Yurkovich
MSMarco Sciacovelli
Marco Sciacovelli
EPEvangelia K. Papachristou
Evangelia K. Papachristou
HBHannah R. Bridges
Hannah R. Bridges
CFChristian Frezza
Christian Frezza
Fumarate hydratase (FH) is an enzyme of the tricarboxylic acid (TCA) cycle mutated in hereditary and sporadic cancers. Despite recent advances in understanding its role in tumorigenesis, the effects of FH loss on mitochondrial metabolism are still unclear. Here, we used mouse and human cell lines to assess mitochondrial function of FH-deficient cells. We found that human and mouse FH-deficient cells exhibit decreased respiration, accompanied by a varying degree of dysfunction of respiratory chain (RC) complex I and II. Moreover, we show that fumarate induces succination of key components of the iron-sulfur cluster biogenesis family of proteins, leading to defects in the biogenesis of iron-sulfur clusters that affect complex I function. We also demonstrate that suppression of complex II activity is caused by product inhibition due to fumarate accumulation. Overall, our work provides evidence that the loss of a single TCA cycle enzyme is sufficient to cause combined RC activity dysfunction.

15 August 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
GPGuillermo Peluffo
Guillermo Peluffo
ASAshim Subedee
Ashim Subedee
NHNicholas W. Harper
Nicholas W. Harper
NKNatalie Kingston
Natalie Kingston
BJBojana Jovanović
Bojana Jovanović
KPKornelia Polyak
Kornelia Polyak
To define transcriptional dependencies of triple-negative breast cancer (TNBC), we identified transcription factors highly and specifically expressed in primary TNBCs and tested their requirement for cell growth in a panel of breast cancer cell lines. We found that EN1 (engrailed 1) is overexpressed in TNBCs and its downregulation preferentially and significantly reduced viability and tumorigenicity in TNBC cell lines. By integrating gene expression changes after EN1 downregulation with EN1 chromatin binding patterns, we identified genes involved in WNT and Hedgehog signaling, neurogenesis, and axonal guidance as direct EN1 transcriptional targets. Quantitative proteomic analyses of EN1-bound chromatin complexes revealed association with transcriptional repressors and coactivators including TLE3, TRIM24, TRIM28, and TRIM33. High expression of EN1 correlated with short overall survival and increased risk of developing brain metastases in patients with TNBC. Thus, EN1 is a prognostic marker and a potential therapeutic target in TNBC. Significance: These findings show that the EN1 transcription factor regulates neurogenesis-related genes and is associated with brain metastasis in triple-negative breast cancer.